US government pledges $2B for new initiative on biomanufacturing

Tyler Patchen

News Reporter

Over the past few days, the Biden administration has been focused on new science efforts, particularly around cancer, and growing biomanufacturing in the US …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

US government pledges $2B for new initiative on biomanufacturing

Tyler Patchen

News Reporter

Sign up to read this article for free.

China startup injects CRISPR therapy into the brain for the first time

Roivant brings rare disease program closer as Immunovant CEO retires

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

US gov­ern­ment pledges $2B for new ini­tia­tive on bio­man­u­fac­tur­ing

Tyler Patchen

News Reporter

Sign up to read this article for free.

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

US government pledges $2B for new initiative on biomanufacturing

China startup injects CRISPR therapy into the brain for the first time

Roivant brings rare disease program closer as Immunovant CEO retires

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence